Equillium Stock Performance
| EQ Stock | USD 0.75 0.03 3.85% |
On a scale of 0 to 100, Equillium holds a performance score of 5. The firm shows a Beta (market volatility) of 1.51, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Equillium will likely underperform. Please check Equillium's potential upside, as well as the relationship between the kurtosis and day typical price , to make a quick decision on whether Equillium's price patterns will revert.
Risk-Adjusted Performance
Modest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Equillium are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak basic indicators, Equillium reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 59.1 M |
Equillium |
Equillium Relative Risk vs. Return Landscape
If you would invest 64.00 in Equillium on December 16, 2024 and sell it today you would earn a total of 11.00 from holding Equillium or generate 17.19% return on investment over 90 days. Equillium is generating 0.4416% of daily returns and assumes 6.3284% volatility on return distribution over the 90 days horizon. Put differently, 56% of stocks are less risky than Equillium on the basis of their historical return distribution, and some 92% of all equities are expected to be superior in generating returns on investments over the next 90 days. Expected Return |
| Risk |
Equillium Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Equillium's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Equillium, and traders can use it to determine the average amount a Equillium's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0698
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | EQ | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 6.33 actual daily | 56 56% of assets are less volatile |
Expected Return
| 0.44 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.07 actual daily | 5 95% of assets perform better |
Based on monthly moving average Equillium is performing at about 5% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Equillium by adding it to a well-diversified portfolio.
Equillium Fundamentals Growth
Equillium Stock prices reflect investors' perceptions of the future prospects and financial health of Equillium, and Equillium fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Equillium Stock performance.
| Return On Equity | -0.2 | ||||
| Return On Asset | -0.0944 | ||||
| Profit Margin | (0.10) % | ||||
| Operating Margin | (0.06) % | ||||
| Current Valuation | 1.57 M | ||||
| Shares Outstanding | 35.43 M | ||||
| Price To Earning | (6.70) X | ||||
| Price To Book | 1.16 X | ||||
| Price To Sales | 0.58 X | ||||
| Revenue | 36.08 M | ||||
| EBITDA | (12.14 M) | ||||
| Cash And Equivalents | 57.56 M | ||||
| Cash Per Share | 1.68 X | ||||
| Total Debt | 824 K | ||||
| Debt To Equity | 0.29 % | ||||
| Book Value Per Share | 0.65 X | ||||
| Cash Flow From Operations | (21.78 M) | ||||
| Earnings Per Share | (0.12) X | ||||
| Total Asset | 50.53 M | ||||
| Retained Earnings | (185.74 M) | ||||
| Current Asset | 60.04 M | ||||
| Current Liabilities | 1.81 M | ||||
About Equillium Performance
Assessing Equillium's fundamental ratios provides investors with valuable insights into Equillium's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Equillium is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California. Equillium operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.Things to note about Equillium performance evaluation
Checking the ongoing alerts about Equillium for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Equillium help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Equillium had very high historical volatility over the last 90 days | |
| Equillium has some characteristics of a very speculative penny stock | |
| The company generated the yearly revenue of 36.08 M. Annual Net Loss to common stockholders was (13.34 M) with gross profit of 45.91 M. | |
| Equillium reports about 57.56 M in cash with (21.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.68, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Equillium has a very weak financial position based on the latest SEC disclosures | |
| Roughly 36.0% of the company shares are held by company insiders |
- Analyzing Equillium's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Equillium's stock is overvalued or undervalued compared to its peers.
- Examining Equillium's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Equillium's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Equillium's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Equillium's stock. These opinions can provide insight into Equillium's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Equillium Stock Analysis
When running Equillium's price analysis, check to measure Equillium's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Equillium is operating at the current time. Most of Equillium's value examination focuses on studying past and present price action to predict the probability of Equillium's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Equillium's price. Additionally, you may evaluate how the addition of Equillium to your portfolios can decrease your overall portfolio volatility.